|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
A10 BA02
|
|
gptkbp:available_on
|
generic medication
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
|
|
gptkbp:casnumber
|
657-24-9
|
|
gptkbp:category
|
B
|
|
gptkbp:chemical_formula
|
C4 H11 N5
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
heart failure
severe liver disease
severe renal impairment
acute or chronic metabolic acidosis
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
gptkb:1922
|
|
gptkbp:dosage_form
|
extended-release tablet
500 mg to 2000 mg daily
|
|
gptkbp:formulation
|
oral tablet
liquid solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Metformin HCl
|
|
gptkbp:interacts_with
|
gptkb:beer
iodinated contrast media
|
|
gptkbp:is_monitored_by
|
renal function
|
|
gptkbp:lifespan
|
about 6 hours
|
|
gptkbp:long_term_use
|
safe
|
|
gptkbp:mechanism_of_action
|
increases insulin sensitivity
decreases hepatic glucose production
|
|
gptkbp:patient_population
|
adults
children over 10 years
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
lactic acidosis
vitamin B12 deficiency
gastrointestinal upset
hypoglycemia (rarely)
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:strength
|
weight neutral
may promote weight loss
|
|
gptkbp:treatment
|
prediabetes
|
|
gptkbp:used_for
|
type 2 diabetes
|
|
gptkbp:bfsParent
|
gptkb:Metformin
|
|
gptkbp:bfsLayer
|
5
|